Do analysts prefer HBIO or LMNX?

Harvard Bioscience presently has a consensus price target of $6.00, suggesting a potential downside of 3.23%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Harvard Bioscience is more favorable than Defiance Daily Target 2X Long LMND ETF. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Defiance Daily Target 2X Long LMND ETF 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer TMO or HBIO?

In the previous week, Thermo Fisher Scientific had 45 more articles in the media than Harvard Bioscience. MarketBeat recorded 46 mentions for Thermo Fisher Scientific and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.55 beat Thermo Fisher Scientific's score of 1.39 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Thermo Fisher Scientific 37 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Harvard Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor HBIO or A?

In the previous week, Agilent Technologies had 18 more articles in the media than Harvard Bioscience. MarketBeat recorded 19 mentions for Agilent Technologies and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.55 beat Agilent Technologies' score of 0.64 indicating that Harvard Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harvard Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Agilent Technologies 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, HBIO or WAT?

Waters has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harvard Bioscience $86.55M 0.32 -$56.70M -$2.17 N/A Waters $3.17B 11.35 $642.63M $7.87 46.47

Does the media favor HBIO or WAT?

In the previous week, Waters had 17 more articles in the media than Harvard Bioscience. MarketBeat recorded 18 mentions for Waters and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.55 beat Waters' score of 0.75 indicating that Harvard Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harvard Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Waters 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ILMN or HBIO?

In the previous week, Illumina had 32 more articles in the media than Harvard Bioscience. MarketBeat recorded 33 mentions for Illumina and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.55 beat Illumina's score of 0.75 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 21 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harvard Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Harvard Bioscience (HBIO) Competitors

$6.20 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$5.99 -0.21 (-3.39%)

As of 08:41 AM Eastern

Compare

HBIO vs. LMNX, TMO, A, WAT, and ILMN

Should you buy Harvard Bioscience stock or one of its competitors? MarketBeat compares Harvard Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harvard Bioscience include Defiance Daily Target 2X Long LMND ETF (LMNX), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Waters (WAT), and Illumina (ILMN). These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Harvard Bioscience (NASDAQ:HBIO) and Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) are both small-cap life sciences tools & services companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Harvard Bioscience's net margin of -11.44%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.44%	-25.78%	-4.37%
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%

Harvard Bioscience presently has a consensus price target of $6.00, suggesting a potential downside of 3.23%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Harvard Bioscience is more favorable than Defiance Daily Target 2X Long LMND ETF.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Defiance Daily Target 2X Long LMND ETF	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.32	-$56.70M	-$2.17	N/A
Defiance Daily Target 2X Long LMND ETF	$437.66M	0.01	$15.17M	$0.51	20.73

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 87.8% of Defiance Daily Target 2X Long LMND ETF shares are owned by institutional investors. 20.3% of Harvard Bioscience shares are owned by insiders. Comparatively, 6.6% of Defiance Daily Target 2X Long LMND ETF shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Harvard Bioscience has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Defiance Daily Target 2X Long LMND ETF has a beta of -11.15, suggesting that its share price is 1,215% less volatile than the broader market.

In the previous week, Harvard Bioscience had 1 more articles in the media than Defiance Daily Target 2X Long LMND ETF. MarketBeat recorded 1 mentions for Harvard Bioscience and 0 mentions for Defiance Daily Target 2X Long LMND ETF. Harvard Bioscience's average media sentiment score of 1.55 beat Defiance Daily Target 2X Long LMND ETF's score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Harvard Bioscience	Very Positive
Defiance Daily Target 2X Long LMND ETF	Neutral

Summary

Harvard Bioscience and Defiance Daily Target 2X Long LMND ETF tied by winning 8 of the 16 factors compared between the two stocks.

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 20.3% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Thermo Fisher Scientific presently has a consensus target price of $613.67, suggesting a potential upside of 29.75%. Harvard Bioscience has a consensus target price of $6.00, suggesting a potential downside of 3.23%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, equities analysts clearly believe Thermo Fisher Scientific is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Thermo Fisher Scientific had 45 more articles in the media than Harvard Bioscience. MarketBeat recorded 46 mentions for Thermo Fisher Scientific and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.55 beat Thermo Fisher Scientific's score of 1.39 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	37 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Thermo Fisher Scientific has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

Thermo Fisher Scientific has a net margin of 15.15% compared to Harvard Bioscience's net margin of -11.44%. Thermo Fisher Scientific's return on equity of 16.86% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.15%	16.86%	8.15%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	3.94	$6.70B	$18.19	26.00
Harvard Bioscience	$86.55M	0.32	-$56.70M	-$2.17	N/A

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 14 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Agilent Technologies?

Harvard Bioscience (NASDAQ:HBIO) and Agilent Technologies (NYSE:A) are both life sciences tools & services companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Harvard Bioscience currently has a consensus price target of $6.00, indicating a potential downside of 3.23%. Agilent Technologies has a consensus price target of $161.71, indicating a potential upside of 19.34%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Agilent Technologies is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.94

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 87.4% of Agilent Technologies shares are owned by institutional investors. 20.3% of Harvard Bioscience shares are owned by insiders. Comparatively, 0.2% of Agilent Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Agilent Technologies has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.32	-$56.70M	-$2.17	N/A
Agilent Technologies	$7.23B	5.29	$1.30B	$4.98	27.21

In the previous week, Agilent Technologies had 18 more articles in the media than Harvard Bioscience. MarketBeat recorded 19 mentions for Agilent Technologies and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.55 beat Agilent Technologies' score of 0.64 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Agilent Technologies	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Harvard Bioscience has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Agilent Technologies has a net margin of 19.55% compared to Harvard Bioscience's net margin of -11.44%. Agilent Technologies' return on equity of 24.33% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.44%	-25.78%	-4.37%
Agilent Technologies	19.55%	24.33%	12.99%

Summary

Agilent Technologies beats Harvard Bioscience on 14 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Waters?

Harvard Bioscience (NASDAQ:HBIO) and Waters (NYSE:WAT) are both life sciences tools & services companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Harvard Bioscience has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Waters has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Waters has a net margin of 11.91% compared to Harvard Bioscience's net margin of -11.44%. Waters' return on equity of 15.60% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.44%	-25.78%	-4.37%
Waters	11.91%	15.60%	8.90%

Harvard Bioscience currently has a consensus target price of $6.00, suggesting a potential downside of 3.23%. Waters has a consensus target price of $394.24, suggesting a potential upside of 7.79%. Given Waters' stronger consensus rating and higher possible upside, analysts clearly believe Waters is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Waters	0 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.75

Waters has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.32	-$56.70M	-$2.17	N/A
Waters	$3.17B	11.35	$642.63M	$7.87	46.47

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 94.0% of Waters shares are owned by institutional investors. 20.3% of Harvard Bioscience shares are owned by company insiders. Comparatively, 0.3% of Waters shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Waters had 17 more articles in the media than Harvard Bioscience. MarketBeat recorded 18 mentions for Waters and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.55 beat Waters' score of 0.75 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Waters	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Waters beats Harvard Bioscience on 14 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Illumina?

Illumina (NASDAQ:ILMN) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Illumina presently has a consensus target price of $138.38, suggesting a potential downside of 14.75%. Harvard Bioscience has a consensus target price of $6.00, suggesting a potential downside of 3.23%. Given Harvard Bioscience's higher probable upside, analysts clearly believe Harvard Bioscience is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.28
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Illumina has a net margin of 19.42% compared to Harvard Bioscience's net margin of -11.44%. Illumina's return on equity of 31.01% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	19.42%	31.01%	12.22%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

89.4% of Illumina shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 2.9% of Illumina shares are held by insiders. Comparatively, 20.3% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Illumina has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Illumina has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.39B	5.59	$850M	$5.50	29.51
Harvard Bioscience	$86.55M	0.32	-$56.70M	-$2.17	N/A

In the previous week, Illumina had 32 more articles in the media than Harvard Bioscience. MarketBeat recorded 33 mentions for Illumina and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.55 beat Illumina's score of 0.75 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	21 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Illumina beats Harvard Bioscience on 12 of the 16 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	INSTRU Industry	Computer Sector	NASDAQ Exchange
Market Cap	$27.96M	$1.46B	$38.75B	$11.98B
Dividend Yield	N/A	0.35%	3.11%	5.55%
P/E Ratio	-2.86	3.35	171.52	23.62
Price / Sales	0.32	1.40	613.07	89.64
Price / Cash	0.53	7.44	48.75	37.25
Price / Book	2.02	3.01	9.64	6.66
Net Income	-$56.70M	-$9.28M	$1.07B	$337.72M
7 Day Performance	-3.13%	0.87%	-3.69%	-3.74%
1 Month Performance	-10.01%	-0.81%	3.66%	0.95%
1 Year Performance	51.63%	6.06%	157.95%	25.35%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	2.7451 of 5 stars	$6.20 flat	$6.00 -3.2%	+51.6%	$27.96M	$86.55M	N/A	490	Positive News Gap Up
LMNX Defiance Daily Target 2X Long LMND ETF	N/A	$14.15 +3.0%	N/A	N/A	$4.67M	$437.66M	27.75	1,325	Positive News Gap Down
TMO Thermo Fisher Scientific	4.8787 of 5 stars	$479.12 -2.9%	$612.24 +27.8%	+17.7%	$183.03B	$44.56B	26.96	125,000	Positive News Gap Up
A Agilent Technologies	4.7725 of 5 stars	$134.56 -1.1%	$162.79 +21.0%	+16.9%	$38.43B	$7.23B	27.09	18,100
WAT Waters	3.3377 of 5 stars	$369.35 -2.0%	$392.76 +6.3%	+4.1%	$37.66B	$3.17B	47.49	7,900

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. LMNX, TMO, A, WAT, and ILMN

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Summary

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Summary

How does Harvard Bioscience compare to Agilent Technologies?

Summary

How does Harvard Bioscience compare to Waters?

Summary

How does Harvard Bioscience compare to Illumina?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. LMNX, TMO, A, WAT, and ILMN

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Is HBIO or LMNX more profitable?

Do analysts prefer HBIO or LMNX?

Which has stronger earnings & valuation, HBIO or LMNX?

Do institutionals and insiders have more ownership in HBIO or LMNX?

Which has more risk & volatility, HBIO or LMNX?

Does the media favor HBIO or LMNX?

Summary

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Do institutionals & insiders have more ownership in TMO or HBIO?

Do analysts rate TMO or HBIO?

Does the media prefer TMO or HBIO?

Which has more risk & volatility, TMO or HBIO?

Is TMO or HBIO more profitable?

Which has stronger valuation and earnings, TMO or HBIO?

Summary

How does Harvard Bioscience compare to Agilent Technologies?

Do analysts rate HBIO or A?

Do institutionals and insiders believe in HBIO or A?

Which has better valuation and earnings, HBIO or A?

Does the media favor HBIO or A?

Which has more risk and volatility, HBIO or A?

Is HBIO or A more profitable?

Summary

How does Harvard Bioscience compare to Waters?

Which has more volatility & risk, HBIO or WAT?

Is HBIO or WAT more profitable?

Do analysts prefer HBIO or WAT?

Which has preferable earnings & valuation, HBIO or WAT?

Do insiders and institutionals hold more shares of HBIO or WAT?

Does the media favor HBIO or WAT?

Summary

How does Harvard Bioscience compare to Illumina?

Do analysts recommend ILMN or HBIO?

Is ILMN or HBIO more profitable?

Do insiders & institutionals hold more shares of ILMN or HBIO?

Which has more volatility & risk, ILMN or HBIO?

Which has higher earnings & valuation, ILMN or HBIO?

Does the media prefer ILMN or HBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools